Beta-defensin 131 (DEFB131)

Beta-defensin 131 (DEFB131) is a small, cationic, disulfide-stabilized antimicrobial peptide predominantly expressed in human epithelial tissues, such as the prostate, small intestine, and testes[1][5]. It is part of the broader beta-defensin family, which functions as key effectors of the innate immune system by directly disrupting microbial membranes and by promoting chemotaxis and activation of immune cells[2][3][4]. DEFB131 expression is upregulated by bacterial triggers via toll-like receptor 2 (TLR2) and NF-κB signaling pathways, resulting in enhanced production of cytokines and chemokines and increased recruitment of monocytes to infection sites[1]. There is no evidence it acts as a classic druggable molecular target (such as a receptor or enzyme), nor that the "DEFB131B" form exists as a distinct, annotated entity in major databases or authoritative literature[5].\n\nKey note:\n- The designation "DEFB131B" is not present in standard protein/gene databases (e.g., UniProt, NCBI Gene), nor in peer-reviewed literature as a separate isoform from DEFB131[5].\n- All available data regarding molecular function, tissue expression, regulation, and immune activity refer to **DEFB131**.\n- No specific therapeutic agents, biomarkers, or clinical targets are reported for DEFB131 or any putative "DEFB131B".

Other names

Beta-defensin 131DEFB131